致编辑的信：通过荧光偏振测定将塔非诺奎重新用作严重急性呼吸综合征冠状病毒2主要蛋白酶的潜在抑制剂。

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Assay and drug development technologies Pub Date : 2023-11-01 Epub Date: 2023-11-07 DOI:10.1089/adt.2023.103

Rui Zhang, Haohao Yan, Gangan Yan, Xiaoping Liu, Yunyu Chen

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Letter to the Editor: Repurposing Tafenoquine as a Potential Inhibitor Against Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease via a Fluorescence Polarization Assay.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Assay and drug development technologies 医学-生化研究方法

CiteScore

3.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： ASSAY and Drug Development Technologies provides access to novel techniques and robust tools that enable critical advances in early-stage screening. This research published in the Journal leads to important therapeutics and platforms for drug discovery and development. This reputable peer-reviewed journal features original papers application-oriented technology reviews, topical issues on novel and burgeoning areas of research, and reports in methodology and technology application. ASSAY and Drug Development Technologies coverage includes: -Assay design, target development, and high-throughput technologies- Hit to Lead optimization and medicinal chemistry through preclinical candidate selection- Lab automation, sample management, bioinformatics, data mining, virtual screening, and data analysis- Approaches to assays configured for gene families, inherited, and infectious diseases- Assays and strategies for adapting model organisms to drug discovery- The use of stem cells as models of disease- Translation of phenotypic outputs to target identification- Exploration and mechanistic studies of the technical basis for assay and screening artifacts